InspireMD, Inc. (NASDAQ:NSPR) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Representatives Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer David Holmes - LifeSci Advisors Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings! Welcome to InspireMD, Third Quarter 2021 Earnings Call. At this time all participants are in a listen-only mode. [Operator Instructions]. Please note, this conference is being recorded. I will now t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Emplo ...

Start Time: 8:30 January 1, 0000 8:51 AM ET InspireMD, Inc. (NASDAQ:NSPR) Q2 2021 Earnings Conference Call August 10, 2021, 08:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Jules Abraham - CORE IR Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the InspireMD Second Quarter 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are in a list ...

Sustained Embolic Protection Disclaimers This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forwardlooking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer i ...

InspireMD, Inc. (NASDAQ:NSPR) Q1 2021 Earnings Conference Call May 11, 2021 8:30 AM ET Company Participants Scott Gordon - President, Core IR, IR Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the InspireMD First Quarter 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Emplo ...

InspireMD, Inc. (NASDAQ:NSPR) Q4 2020 Earnings Conference Call March 9, 2021 8:30 AM ET Company Participants Scott Gordon - President, Core IR, Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the InspireMD Year End 2020 Financial Results and Corporate Update Conference Call. At this time, all participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) [X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction of incorporation or organization) 4 Men ...

Financial Data and Key Metrics Changes - Total revenues for Q3 2020 were $980,000, a 4.4% increase from $939,000 in Q3 2019, and a 213% increase from $313,000 in Q2 2020 [18][26] - Gross profit for Q3 2020 was $298,000, a 133% increase from $128,000 in Q3 2019, with gross margin rising to 30.4% from 13.6% [28] - Net loss for Q3 2020 was $2,233,000 or $0.06 per share, compared to a net loss of $2,070,000 or $1.26 per share in Q3 2019 [31] Business Line Data and Key Metrics Changes - Sales volume of MGuard EPS increased by 69% from $87,000 in Q3 2019 to $147,000 in Q3 2020, driven by a recent tender win [26] - Sales volume of CGuard Prime EPS decreased by 2.2% from $852,000 in Q3 2019 to $833,000 in Q3 2020, attributed to the return of non-emergency procedures [27] Market Data and Key Metrics Changes - The resurgence of elective procedures in key markets led to a 213% increase in total sales compared to Q2 2020, with nearly 50% of sales occurring in the last month of the quarter [9][18] - New restrictions due to COVID-19 create uncertainty in market impact moving forward [19] Company Strategy and Development Direction - The company aims to broaden market share in endovascular carotid artery stenting (CAS) procedures and position CGuard EPS as a first-line stent solution [22] - Global expansion efforts are focused on high-priority markets like China and Japan, with ongoing discussions for distribution partnerships [24][25] - The company is investing in new leadership to drive growth objectives and enhance commercial focus [8][12][13] Management's Comments on Operating Environment and Future Outlook - Management expresses cautious optimism about market recovery despite ongoing uncertainties due to COVID-19 [7][19] - The company remains committed to improving clinical outcomes and maintaining a focus on stroke prevention and carotid artery disease management [52] Other Important Information - The FDA granted conditional approval for the pivotal study of CGuard EPS, with preparations underway for the trial [10][11] - Key hires include a new Vice President of Business Development and a Senior Vice President of Global Sales and Marketing to enhance strategic initiatives [12][13] Q&A Session Summary Question: How did the company secure Dr. Roubin as a board member? - The connection was made through Dr. Christina Brennan, leading to discussions that highlighted Dr. Roubin's valuable insights and experience [34][35] Question: How will the company strategically move the business during COVID? - The company is focusing on being commercially driven and ensuring that CGuard EPS is prioritized among distribution partners [37][38] Question: What is the timeline for advanced delivery options? - The company aims to have new products to market in a meaningful timeframe within 2021, with progress being made on a new transfemoral delivery system [42][43] Question: When will the CGuard trial begin enrolling patients? - The company is finalizing decisions on trial partners and site selection, with a clearer schedule expected soon [44][45]